SeaGen

Seagen Reports Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, July 29, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical trials, SeaGen

Cost of Sales: Cost of sales for the second quarter and year-to-date in 2021 were $78.1 million and $142.2 million, respectively, compared to $48.2 million and $77.7 million for the same periods in 2020.

Key Points: 
  • Cost of Sales: Cost of sales for the second quarter and year-to-date in 2021 were $78.1 million and $142.2 million, respectively, compared to $48.2 million and $77.7 million for the same periods in 2020.
  • Net Loss: Net loss for the second quarter of 2021 was $84.6 million, or $0.47 per diluted share, compared to net loss of $21.2 million, or $0.12 per diluted share, for the second quarter of 2020.
  • Seagen anticipates 2021 revenues, operating expenses and other costs to be in the ranges shown in the table below, unchanged from the Company's previous financial guidance provided on February 11, 2021.
  • Seagen management will host a conference call and webcast with supporting slides to discuss its second quarter 2021 and year-to-date financial results and provide an update on business activities.

Transcenta Announces Orphan Drug Designation Granted to TST001 for Treatment of Gastric and Gastroesophageal Junction

Retrieved on: 
Thursday, July 29, 2021
Drugs, Cancer treatments, Clinical medicine, Monoclonal antibodies, Orphan drugs, Antineoplastic drugs, Breakthrough therapy, Bristol-Myers Squibb, Pembrolizumab, SeaGen

SUZHOU, China, July 28, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to TST001, its anti-Claudin18.2 monoclonal antibody currently in Phase I clinical trial, for the treatment of patients with gastric cancer or gastroesophageal junction (GC/GEJ).

Key Points: 
  • SUZHOU, China, July 28, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to TST001, its anti-Claudin18.2 monoclonal antibody currently in Phase I clinical trial, for the treatment of patients with gastric cancer or gastroesophageal junction (GC/GEJ).
  • According to preclinical and clinical data, TST001 displayed potent anti-tumor activities in tumor model of gastric cancer or patient of gastric cancer expressing Claudin18.2.
  • At present, the treatment options of gastric cancer expressing Claudin18.2 are very limited other than surgical resection, chemotherapy and most recently immunotherapy.
  • Orphan Drug Designation (ODD) is granted by the FDA to drugs intended to treat rare disorders that affect fewer than 200,000 people in the U.S.

Synaffix Announces Deal with ProfoundBio Worth up to $246 Million Providing Access to Multiple Novel Linker-Payload Technologies

Retrieved on: 
Thursday, July 22, 2021
Oncology, Health, Technology, Other Technology, Clinical trials, Pharmaceutical, Biotechnology, Synaffix, SeaGen, Linker, ACC, Health care, Companies, Antibody-drug conjugate, The Synaffix ADC Platform Technology, Synaffix B.V., ProfoundBio, THE SYNAFFIX ADC PLATFORM TECHNOLOGY, SYNAFFIX B.V., PROFOUNDBIO

The deal provides access to multiple novel linker-payload technologies developed by Synaffix and includes access to the GlycoConnect glycan conjugation and HydraSpace polar spacer technologies, both of which are known to optimize the therapeutic properties (efficacy and safety) of ADCs.

Key Points: 
  • The deal provides access to multiple novel linker-payload technologies developed by Synaffix and includes access to the GlycoConnect glycan conjugation and HydraSpace polar spacer technologies, both of which are known to optimize the therapeutic properties (efficacy and safety) of ADCs.
  • Under the terms of the agreement, Synaffix is eligible to receive upfront and potential milestone payments worth up to $246 million, plus tiered royalties on net sales.
  • Through our collaboration with Synaffix, we can access multiple potent ADC linker-payloads and efficiently optimize the competitive position of our therapeutic pipeline.
  • The ProfoundBio team brings multiple decades of valuable ADC development experience from Seattle Genetics (now Seagen) and MSD.

U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer

Retrieved on: 
Friday, July 9, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical trials, Cancer treatments, Clinical medicine, Drugs, Breakthrough therapy, Cancer immunotherapy, Orphan drugs, Monoclonal antibodies, Antibody-drug conjugates, Enfortumab vedotin, Transitional cell carcinoma, PD-1 and PD-L1 inhibitors, SeaGen, the EV-301 Trial, the EV-201 Trial, PADCEV® (enfortumab vedotin-ejfv), Seagen, Astellas, the Seagen and Astellas Collaboration, THE EV-301 TRIAL, THE EV-201 TRIAL, PADCEV® (ENFORTUMAB VEDOTIN-EJFV), SEAGEN, ASTELLAS, THE SEAGEN AND ASTELLAS COLLABORATION

The EV-301 trial compared PADCEV to chemotherapy in adult patients (n=608) with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor.

Key Points: 
  • The EV-301 trial compared PADCEV to chemotherapy in adult patients (n=608) with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor.
  • PADCEV is the first and only FDA-approved therapy for patients with locally advanced or metastatic urothelial cancer who have received immunotherapy and cannot receive cisplatin, said Roger Dansey, M.D., Chief Medical Officer, Seagen.
  • In clinical trials, 14% of the 680 patients treated with PADCEV developed hyperglycemia; 7% of patients developed Grade 3-4 hyperglycemia.
  • Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicenter, single-arm, phase 2 trial.

Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2021 Financial Results on July 29, 2021

Retrieved on: 
Thursday, July 8, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, SeaGen, SeaGen, NASDAQ, Finance, Economy of the United States, Health care

Seagen Inc. (Nasdaq: SGEN) today announced that it will report its second quarter 2021 financial results on Thursday, July 29, 2021 after the close of U.S. financial markets.

Key Points: 
  • Seagen Inc. (Nasdaq: SGEN) today announced that it will report its second quarter 2021 financial results on Thursday, July 29, 2021 after the close of U.S. financial markets.
  • Following the announcement, Company management will host a conference call and webcast discussion of the results and provide a business update.
  • Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in peoples lives.
  • Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union.

Crescendo to Participate in Upcoming Investor Events

Retrieved on: 
Wednesday, July 7, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Life sciences, Biotechnology, Sofinnova, Biopharmaceutical, Astellas Pharma, SeaGen

Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that senior members of the executive team will be participating at the following events.

Key Points: 
  • Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that senior members of the executive team will be participating at the following events.
  • They look forward to meeting investors to discuss the Companys business strategy, technology, discovery platform and development programmes.
  • Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody therapeutics.
  • Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

Seagen to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

Retrieved on: 
Wednesday, June 2, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, SeaGen, SeaGen, Goldman Sachs, Banks, Companies, Economy of New York City

Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 2:10 p.m. Eastern Time.

Key Points: 
  • Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 2:10 p.m. Eastern Time.
  • The presentation will be webcast live and available for replay from Seagens website at www.seagen.com in the Investors section.
  • Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in peoples lives.
  • Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union.

Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration

Retrieved on: 
Wednesday, June 2, 2021
Genmab, Companies, Biotechnology companies, Pharmaceutical companies, SeaGen

Genmab has option to develop and commercialize up to three therapeutic candidates; Bolt has option to participate in development and commercialization of one candidate

Key Points: 
  • Genmab has option to develop and commercialize up to three therapeutic candidates; Bolt has option to participate in development and commercialization of one candidate
    COPENHAGEN, Denmark and REDWOOD City, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Genmab A/S (Nasdaq: GMAB) and Bolt Biotherapeutics, Inc. (Nasdaq:BOLT) announced today that the companies have entered into an oncology research and development collaboration.
  • This research collaboration will evaluate multiple bispecific ISAC concepts to identify up to three clinical candidates for development.
  • Genmab will fund the research, along with the preclinical and clinical development of these candidates through clinical proof of concept.
  • Under the terms of the agreement, Genmab will pay Bolt an upfront payment of USD 10 million.

Nurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its Board of Directors

Retrieved on: 
Tuesday, June 1, 2021
Life sciences, Biotechnology, Health care, SeaGen, Antibody-drug conjugate, Biopharmaceutical

SAN FRANCISCO, June 01, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Clay Siegall, Ph.D., to its board of directors.

Key Points: 
  • SAN FRANCISCO, June 01, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Clay Siegall, Ph.D., to its board of directors.
  • Today, Seagen has three FDA-approved medicines: Adcetris, Padcev and Tukysa and is an industry leader in antibody-drug conjugate (ADC) technology and development.
  • Concurrent with the appointment of Dr. Siegall, Leon Chen, Ph.D., a partner at The Column Group, resigned from the Nurix board, effectiveMay 28, 2021.
  • Nurix thanks Dr. Chen for his support and many contributions to the company during his tenure on the Nurix board.

Astellas to Present Data from Expanding Oncology Portfolio During the 2021 ASCO Annual Meeting

Retrieved on: 
Monday, May 17, 2021
Biotechnology, Companies, Life sciences, SeaGen, Astellas Pharma, Enfortumab vedotin, Forward-looking statement, Monomethyl auristatin E, SeaGen

In the United States, Astellas and Seagen co-promote enfortumab vedotin.

Key Points: 
  • In the United States, Astellas and Seagen co-promote enfortumab vedotin.
  • In the Americas outside the US, Seagen holds responsibility for commercialization activities and regulatory filings.
  • Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.
  • A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements.